Aptose Biosciences INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
SCHEDULE 13D/A: Hanmi Pharmaceutical Converts Debt to Equity in Aptose Biosciences, Increases Stake to 19.93% Amidst New Capital Raise Plans
Hanmi Pharmaceutical Co., Ltd. has converted $1.51 million of debt into common shares of Aptose Biosciences Inc., increasing its beneficial ownership to 19.93% and securing enhanced investor rights, while Aptose plans a new $15 million capital raise.